Here are four things to know:
1. Cynata is developing an induced pluripotent stem cell therapy designed to treat organ or bone marrow transplant complications. The company recently completed the first phase of clinical trials in the U.K. and found the iPS cell treatment to be safe and effective.
2. Cynata’s CYP-001 treatment received FDA orphan drug designation.
3. Clinical trials will enter their second phase in 2019. Marketing approval is aimed for 2022 at the latest.
4. Fujifilm holds a 10 percent-plus stake in Cynata. The companies entered into a capital tie-up in 2016.
More articles on biologics:
Hospital for Special Surgery researchers launch study of Organogenesis’ ReNu for knee defects: 5 insights
Viewpoint: A stem cell provider registry program will improve treatments
Baxter receives FDA clearance for posterolateral spinal fusion bone graft substitute: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
